[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-415674-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-415674-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","outcomes-of-car-t-cell-therapy-in-high-grade-b-cell-lymphomas-compared-to-dlbcl-weighted-comparison-analysis","Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL - Weighted comparison analysis","","High-grade B-cell lymphomas (HGBL), including double-hit/triple-hit and non-specified variants, show poor prognosis after first-line therapy failure. This prospective cohort study compared outcomes of anti-CD19 CAR T-cell therapy between HGBL and diffuse large B-cell lymphoma (DLBCL) using weighted log-rank tests and weighted Cox models, focusing on overall survival after CAR T-cell failure. Among 432 patients, weighted analyses found a significant 2-year overall survival difference favoring DLBCL, without clear differences in progression-free survival or duration of response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/outcomes-of-car-t-cell-therapy-in-high-grade-b-cell-lymphomas-compared-to-dlbcl-weighted-comparison-analysis/415674/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/outcomes-of-car-t-cell-therapy-in-high-grade-b-cell-lymphomas-compared-to-dlbcl-weighted-comparison-analysis/415674.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main finding comparing HGBL and DLBCL after CAR T-cell therapy?","Question",{"text":63,"@type":64},"After weighting, a significant difference in 2-year overall survival was observed between HGBL and DLBCL, with DLBCL showing better survival. Progression-free survival and duration of response were not significantly different.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were included and what were the follow-up times?",{"text":68,"@type":64},"The study cohort included 432 patients (HGBL n=78; DLBCL n=354). Median follow-up was 22.8 months for HGBL and 18 months for DLBCL.",{"name":70,"@type":61,"acceptedAnswer":71},"Did CAR T-cell therapy expansion or lymphoma subtype (HGBL-DH/TH) affect outcomes?",{"text":72,"@type":64},"CAR T-cell therapy expansion in HGBL did not correlate with response. There was no statistically significant difference in progression-free survival and overall survival between HGBL-DH/TH lymphomas and other high-grade histotypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},415674,1790876553,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","REGULAR ARTICLE  \nOutcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis  \nAnna Dodero,1,* Giusy Ceparano,1, 2,* Beatrice Casadei,3 Piera Angelillo,4 Stefania Bramanti,5 Maria Chiara Tisi,6 Silva Ljevar,7 Federico Stella,2 Annalisa Chiappella,1 Barbara Botto,8 Ilaria Cutini,9 Giada Zanirato,1 Patrizia Chiusolo,10 Anna Maria Barbui, 11 Mirko Farina, 12 Alice Di Rocco, 13 Giovanni Grillo, 14 Jacopo Olivieri, 15 Mauro Krampera, 16 Marco Ladetto, 17 Anna Guidetti,1, 2 Pier Luigi Zinzani,3, 18 Cristiana Carniti,1 and Paolo Corradini 1, 2  \n1 Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy; 2 Division of Hematology and Stem Cell Transplantation, University of Milan, Milan, Italy; 3 Istituto di Ematologia “Ser`agnoli,” Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 4 Lymphoma Unit, Department of OncoHematology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele Milan, Milan, Italy; 5 Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Transplantation Unit Department of Oncology and Hematology, Milan, Italy; 6 Hematology Unit, San Bortolo Hospital, Azienda Unita' Sanitaria Locale Socio Sanitaria 8 Berica, Vicenza, Italy; 7 Unit of Biostatistics for Clinical Research, Department of Data Science, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy; 8 Struttura Complessa Ematologia, Azienda Ospedaliera Universitaria Citt`a della Salute e della Scienza Torino, Turin, Italy; 9 Struttura Organizzativa Dipartimentale Terapie Cellulari e Medicina Trasfusionale, Trapianto di Midollo Osseo, Ospedale Careggi, Firenze, Italy; 10 Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli-Istituto di Ricovero e Cura a Carattere Scientifico, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit`a Cattolica del Sacro Cuore, Rome, Italy; 11 Unit`a di Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy; 12 Unit of Blood Disease and Bone Marrow Transplantation, and Unit of Hematology, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy; 13 Hematology, Department of Translational and Precision Medicine, Univ Sapienza Roma, Rome, Italy; 14 Dipartimento di Ematologia e trapianto di midollo, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy; 15 Dipartimento di Clinica Ematologica, Centro Trapianti e Terapie Cellulari “Carlo Melzi,” Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; 16 Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy; 17 Dipartimento di Medicina Traslazionale Universit`a del Piemonte Orientale ed Struttura complessa a Direzione Universitaria Ematologia Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; and 18 Dipartimento di Scienze Mediche e Chirurgiche, Universit`a di Bologna, Bologna, Italy  \nKey Points  \n• After weighting, a significant difference in 2-year OS but not in PFS or DOR was observed between HGBL and DLBCL.  \n• The 2-year OS following CAR T-cell infusion (after weighted log-rank tests) remained significantly inferior for HGBL compared to DLBCL.  \nHigh-grade B-cell lymphomas (HGBL, including double-hit/triple-hit [HGBL-DH/TH], and HGBL not otherwise specified) have a poor prognosis upon failure of first-line therapy. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for third-line aggressive large B-cell lymphomas (LBCL) resulted in long-term remission in ≤40% of patients. This study evaluated factors that can","cbCaiip6Ex1WdT2B","https://ap.wps.com/l/cbCaiip6Ex1WdT2B","pdf",819795,11,"English","# Key Points\n## Study comparison and weighted survival outcomes\n## Safety and secondary malignancies","[{\"question\":\"What was the main finding comparing HGBL and DLBCL after CAR T-cell therapy?\",\"answer\":\"After weighting, a significant difference in 2-year overall survival was observed between HGBL and DLBCL, with DLBCL showing better survival. Progression-free survival and duration of response were not significantly different.\"},{\"question\":\"How many patients were included and what were the follow-up times?\",\"answer\":\"The study cohort included 432 patients (HGBL n=78; DLBCL n=354). Median follow-up was 22.8 months for HGBL and 18 months for DLBCL.\"},{\"question\":\"Did CAR T-cell therapy expansion or lymphoma subtype (HGBL-DH/TH) affect outcomes?\",\"answer\":\"CAR T-cell therapy expansion in HGBL did not correlate with response. There was no statistically significant difference in progression-free survival and overall survival between HGBL-DH/TH lymphomas and other high-grade histotypes.\"}]","Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL - Weighted comparison analysis | PDF",1790602391,28]